Medicines Patent Pool selects Fidson Healthcare for generic antiviral manufacturing
What happened
The Medicines Patent Pool has managed a voluntary licensing agreement selecting Fidson Healthcare Plc to manufacture a generic version of Roche’s influenza antiviral, baloxavir marboxil. This agreement allows the generic supply to 129 countries, with Fidson Healthcare Plc representing Nigeria among the manufacturers. The announcement was made at a side event organized by the Medicines Patent Pool.
From punchng.com
Why it matters
The agreement aims to expand access to influenza treatment and diversify medicine supply chains globally. Fidson Healthcare Plc is one of 11 manufacturers chosen across nine countries under the voluntary licensing agreement between the Medicines Patent Pool and Hoffmann-La Roche.
From punchng.com
Who's involved
- Medicines Patent PoolOrganization managing the voluntary licensing agreement
- Hoffmann-La RocheSwiss company whose influenza antiviral, baloxavir marboxil, is being licensed
- Fidelis AyebaeNigerian Managing Director of Fidson Healthcare Plc
- NigeriaNigerian state where Fidson Healthcare Plc is based
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Fidelis AyebaeSpeculative
Fidson Healthcare Plc's leadership might see increased standing and revenue from the contract win.
- Hoffmann-La RocheSpeculative
Hoffmann-La Roche might expand its market reach through the successful execution of the licensing agreement.
- federal government of NigeriaSpeculative
The federal government of Nigeria might see increased national revenue and foreign exchange earnings from the global manufacturing role.